Stocktoria
Q32 Bio Inc. QTTB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-28
Q32 Bio Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 31.5% | — | 725.5% | -4154.6% | -282.4% |
| Net margin | 55.5% | — | 808.0% | -156.0% | -281.9% |
| FCF margin | -62.4% | — | 280.9% | -3583.1% | -330.1% |
| Return on assets | 48.3% | -51.7% | -114.2% | -2.2% | -45.2% |
| Return on equity | 71.0% | -841.1% | 29.4% | 3.8% | -56.4% |
| Current ratio | 4.85 | 4.97 | 2.04 | 8.02 | 11.14 |
| Revenue growth | — | -100.0% | -307.3% | -90.6% | 1157.3% |
Source: SEC EDGAR filings · CIK 0001661998 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.